Cardiac and cardiomyocyte therapy and drug testing, cardiotoxicity testing, drug discovery
In order to develop new cardiac therapies and predict pre-clinical cardiac drug toxicity, the effect of pharmaceuticals on cardiac and cardiomyocyte function needs to be measured in ways that translate accurately to patient response. At the Maynes Lab, we specialize in models of human heart function, using human patient and stem-cell- derived tissue constructs, including the development of novel platforms for high-throughput quantification of drug activity. Using these technologies and methodology, we can determine the comprehensive effects of drugs on human cardiac/cardiomyocyte activity either for therapy discovery or to predict drug toxicity.
Cardiac tissue modeling, pre-clinical drug testing or development, prediction of drug cardiac activity for therapy discovery or for toxicity.
- Life sciences, pharmaceuticals and medical equipment
Specialized labs and equipment
xCELLigence RTCA Cardio ECR System
Cardiomyocyte/iPSC experimentation in customized atmospheres (i.e. hypoxia)